Q3 FY2026 · ended Sep 30, 2026 · Revenue $12.07M, +36.3% YoY · Filed Oct 28, 2026
ClearPoint Neuro, Inc. (CLPT) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $12.1 million and a net loss of $7.5 million. Free cash flow was -$20.2 million. As of Sep 30, 2026 it held $46.2 million in cash and investments and $73.7 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CLPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1285550
- Former names
- MRI INTERVENTIONS, INC. (until Feb 11, 2020); SURGIVISION INC (until Oct 22, 2010); SURGI VISION INC (until May 2, 2007)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $12.1M | $10.9M | $12.1M | $10.4M | $8.9M |
| Operating income | -$6.3M | -$10.2M | -$8.5M | -$7.0M | -$5.3M |
| Net income | -$7.5M | -$11.3M | -$9.6M | -$7.8M | -$5.9M |
| Diluted EPS | -$0.24 | -$0.38 | -$0.32 | -$0.27 | -$0.21 |
| Operating cash flow | -$20.1M | -$7.0M | -$8.0M | -$12.1M | -$3.1M |
| Free cash flow | -$20.2M | -$7.2M | -$8.6M | -$12.1M | -$3.3M |
| Total assets | $112.7M | $86.7M | $93.4M | $97.7M | $60.4M |
| Total liabilities | $85.5M | $76.0M | $74.6M | $69.7M | $44.5M |
| Stockholders' equity | $27.3M | $10.8M | $18.8M | $28.0M | $15.9M |
| Cash and investments | $46.2M | $29.4M | $35.6M | $45.9M | $38.2M |
| Total debt | $73.7M | $63.9M | $63.6M | $58.2M | $35.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 1006 ClearPoint Neuro, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.